Neurocrine Biosciences (NBIX) Total Liabilities (2010 - 2026)

Neurocrine Biosciences' Total Liabilities history runs 17 years deep, the most recent figure standing at $1.5 billion for Q1 2026.

• Quarterly Total Liabilities rose 30.1% year-over-year to $1.5 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 billion (up 30.1% YoY) and the FY2025 annual result came in at $1.4 billion, up 22.09% from the prior year.
• Total Liabilities was $1.5 billion for Q1 2026 at Neurocrine Biosciences, up from $1.4 billion in the prior quarter.
• Across five years, Total Liabilities topped out at $1.5 billion in Q1 2026 and bottomed at $582.3 million in Q2 2022.
• A 5-year average of $953.5 million and a median of $846.1 million in 2023 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2022 — Total Liabilities slipped 14.01% — and 2024, when it soared 60.86%.
• Neurocrine Biosciences' Total Liabilities stood at $660.9 million in 2022, then jumped by 54.24% to $1.0 billion in 2023, then rose by 10.75% to $1.1 billion in 2024, then advanced by 22.09% to $1.4 billion in 2025, then climbed by 8.73% to $1.5 billion in 2026.
• Business Quant data shows NBIX's Total Liabilities at $1.5 billion in Q1 2026, $1.4 billion in Q4 2025, and $1.3 billion in Q3 2025.